Fig. 8

The concentrations of VEGF in the haematoma and serum quantified by ELISA. a The concentrations of VEGFA in surgical patients, unpaired Student’s t test, ^****P < 0.001, ^***P = 0.004. b The changes of VEGFA in serum after surgery, unpaired Student’s t test, ^****P < 0.001. c The concentrations of VEGFA in conservatively treated patients who have good efficacy or switched to surgery. Conservative treatment and good prognosis, one-way ANOVA, P < 0.001; Bonferroni test, before vs. after (5 weeks), ^****P < 0.001; before vs. after (7 days), ^***P = 0.003. After (7 days) (switch to surgery vs. conservative treatment and good prognosis, unpaired Student’s t test, ^*P = 0.043). d Changes of VEGFA in patients treated with a combination regimen or ATO monotherapy. ATO group, one-way ANOVA, P = 0.007; Bonferroni test, before vs. after (5 weeks), ^**P = 0.007. ATO + DEX group, one-way ANOVA, P < 0.001; Bonferroni test, before vs. after (5 weeks), ^****P < 0.001; before vs. after (7 days), ^***P = 0.001. After (7 days) (ATO vs. ATO + DEX, unpaired Student’s t test, ^*P = 0.013). After (5 weeks) (ATO vs. ATO + DEX, unpaired student’s t test, ^***P = 0.001). Note: ATO, atorvastatin; DEX, dexamethasone; non-drug, patients undergoing surgery directly without conservative treatment